NASDAQ:CPRX Catalyst Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.95 +0.07 (+1.02%) (As of 06/29/2022 12:00 AM ET) Add Compare Share Today's Range$6.81▼$6.9850-Day Range$6.23▼$8.2552-Week Range$4.81▼$8.65Volume751,589 shsAverage Volume1.15 million shsMarket Capitalization$714.32 millionP/E Ratio16.55Dividend YieldN/APrice Target$10.92 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Stock Forecast (MarketRank)Overall MarketRank™2.99 out of 5 starsMedical Sector18th out of 1,432 stocksPharmaceutical Preparations Industry3rd out of 685 stocksAnalyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 3.1 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.92, Catalyst Pharmaceuticals has a forecasted upside of 57.1% from its current price of $6.95.Amount of Analyst CoverageCatalyst Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 5.0 Community Rank Outperform VotesCatalyst Pharmaceuticals has received 457 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCatalyst Pharmaceuticals has received 148 “underperform” votes. (Add your “underperform” vote.)Community SentimentCatalyst Pharmaceuticals has received 75.54% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote “Outperform” if you believe CPRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CPRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,665.00 in company stock.Percentage Held by Insiders12.80% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.28% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 19.40% in the coming year, from $0.67 to $0.80 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 16.55, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.06.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 16.55, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.25.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Catalyst Pharmaceuticals (NASDAQ:CPRX)Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.Read More CPRX Stock News HeadlinesJune 28, 2022 | marketbeat.com3 Robinhood Favs the Street Loves Too (CPRX)Given the largely speculative nature of the Robinhood-100 list, it’s not often that fundamentally focused research firms agree with the largely social media-driven retail trader. Yet the Street and Robinhooders are clearly on board with the growth potential of these three names.June 24, 2022 | americanbankingnews.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Gary Ingenito Sells 6,152 Shares of StockJune 10, 2022 | americanbankingnews.com$0.17 Earnings Per Share Expected for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) This QuarterJune 9, 2022 | finance.yahoo.comCatalyst (CPRX) Up 6.9% Since Last Earnings Report: Can It Continue?June 4, 2022 | finance.yahoo.comIs Now the Time to Buy This Risky Stock With Huge Upside Potential?May 13, 2022 | seekingalpha.comCatalyst Pharmaceuticals, Inc.'s (CPRX) CEO Patrick McEnany on Q1 2022 Results - Earnings Call TranscriptMay 11, 2022 | seekingalpha.comCatalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q1 2022 Results - Earnings Call TranscriptMay 11, 2022 | seekingalpha.comCatalyst Pharmaceuticals Q1 earnings rise Y/Y; reaffirms FY22 revenue outlookMay 11, 2022 | finance.yahoo.comCatalyst Pharmaceuticals (NASDAQ:CPRX) pulls back 10% this week, but still delivers shareholders solid 27% CAGR over 5 yearsMay 10, 2022 | finance.yahoo.comCatalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate UpdateMay 9, 2022 | seekingalpha.comCatalyst Pharmaceuticals Q1 2022 Earnings PreviewApril 25, 2022 | finance.yahoo.comCatalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022April 6, 2022 | finance.yahoo.comCatalyst Pharmaceutical (CPRX) is a Top-Ranked Momentum Stock: Should You Buy?See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CPRX CUSIPN/A CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees76Year Founded2002Company Calendar Last Earnings5/10/2022Today6/29/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$10.92 High Stock Price Forecast$12.00 Low Stock Price Forecast$8.75 Forecasted Upside/Downside+57.1%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.42 Trailing P/E Ratio16.55 Forward P/E Ratio10.37 P/E GrowthN/ANet Income$39.48 million Net Margins29.31% Pretax Margin39.19% Return on Equity23.95% Return on Assets21.27% Debt Debt-to-Equity RatioN/A Current Ratio9.64 Quick Ratio9.30 Sales & Book Value Annual Sales$140.83 million Price / Sales5.07 Cash Flow$0.41 per share Price / Cash Flow17.13 Book Value$2.01 per share Price / Book3.46Miscellaneous Outstanding Shares102,780,000Free Float89,624,000Market Cap$714.32 million OptionableOptionable Beta1.30 Social Links Catalyst Pharmaceuticals Frequently Asked Questions Should I buy or sell Catalyst Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Catalyst Pharmaceuticals stock. View analyst ratings for Catalyst Pharmaceuticals or view top-rated stocks. What is Catalyst Pharmaceuticals' stock price forecast for 2022? 4 brokers have issued twelve-month target prices for Catalyst Pharmaceuticals' stock. Their CPRX stock forecasts range from $8.75 to $12.00. On average, they predict Catalyst Pharmaceuticals' share price to reach $10.92 in the next year. This suggests a possible upside of 57.1% from the stock's current price. View analysts' price targets for Catalyst Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Catalyst Pharmaceuticals' stock price performed in 2022? Catalyst Pharmaceuticals' stock was trading at $6.77 at the beginning of the year. Since then, CPRX shares have increased by 2.7% and is now trading at $6.95. View the best growth stocks for 2022 here. When is Catalyst Pharmaceuticals' next earnings date? Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Catalyst Pharmaceuticals. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.14 by $0.02. The biopharmaceutical company had revenue of $43.09 million for the quarter, compared to analysts' expectations of $43.17 million. Catalyst Pharmaceuticals had a net margin of 29.31% and a trailing twelve-month return on equity of 23.95%. During the same period in the prior year, the company posted $0.09 EPS. View Catalyst Pharmaceuticals' earnings history. What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings? Catalyst Pharmaceuticals issued an update on its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $195.00 million-$205.00 million, compared to the consensus revenue estimate of $199.99 million. Who are Catalyst Pharmaceuticals' key executives? Catalyst Pharmaceuticals' management team includes the following people: Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 75, Pay $1.05M) (LinkedIn Profile)Ms. Alicia Grande C.M.A., CPA, CMA, CPA, Chief Accounting Officer, VP, Treasurer & CFO (Age 51, Pay $617.94k)Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 60, Pay $745.71k)Dr. Gary Ingenito, Chief Medical & Regulatory Officer (Age 66, Pay $706.86k) (LinkedIn Profile)Dr. Preethi Sundaram Ph.D., Chief Strategy Officer (Age 46, Pay $511.25k)Ms. Mary Coleman, VP & Head of Investor RelationsMr. Brian Elsbernd J.D., Chief Compliance Officer & Chief Legal Officer (Age 58)Mr. Pete Curry Sr., VP of SalesMr. Jeffrey Del Carmen, Chief Commercial Officer (Age 51)Mr. Philip B. Schwartz, Corp. Sec. (Age 67) Who are some of Catalyst Pharmaceuticals' key competitors? Some companies that are related to Catalyst Pharmaceuticals include Indivior (INVVY), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), CureVac (CVAC), Insmed (INSM), Arvinas (ARVN), ACADIA Pharmaceuticals (ACAD), EQRx (EQRX), HUTCHMED (HCM), Global Blood Therapeutics (GBT), Schrödinger (SDGR), Sage Therapeutics (SAGE), ChemoCentryx (CCXI), Ironwood Pharmaceuticals (IRWD) and OPKO Health (OPK). View all of CPRX's competitors. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). What is Catalyst Pharmaceuticals' stock symbol? Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX." How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Catalyst Pharmaceuticals' stock price today? One share of CPRX stock can currently be purchased for approximately $6.95. How much money does Catalyst Pharmaceuticals make? Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $714.32 million and generates $140.83 million in revenue each year. The biopharmaceutical company earns $39.48 million in net income (profit) each year or $0.42 on an earnings per share basis. How many employees does Catalyst Pharmaceuticals have? Catalyst Pharmaceuticals employs 76 workers across the globe. When was Catalyst Pharmaceuticals founded? Catalyst Pharmaceuticals was founded in 2002. How can I contact Catalyst Pharmaceuticals? Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for Catalyst Pharmaceuticals is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at [email protected], or via fax at 305-529-0933. This page (NASDAQ:CPRX) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
